These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [HBXIP expression in gastric adenocarcinoma predicts poor prognosis].
    Author: Piao JJ, Li N, Wang YX, Lin ZH, Liu SP.
    Journal: Zhonghua Bing Li Xue Za Zhi; 2017 Feb 08; 46(2):88-92. PubMed ID: 28173666.
    Abstract:
    Objective: To investigate the localization of HBXIP protein over-expression in gastric adenocarcinoma, and its prognostic significance. Methods: HBXIP localization was detected by immunofluorescence in AGS gastric cancer cell line, and by immunohistochemical staining in 97 gastric adenocarcinomas, 41 adjacent non-tumor tissues and 13 gastric adenoma tissues. Correlation between HBXIP expression and clinicopathological features of gastric cancer patients was evaluated by Chi-square and Fisher's exact tests. Overall survival rates were calculated using Kaplan-Meier method. Results: HBXIP was mainly expressed in the cytoplasm of gastric cancer. The positive and strongly positive expression rates of HBXIP protein in gastric cancers were 68.0% (66/97) and 49.5% (48/97) respectively, and were significantly higher than those in adjacent non-tumor tissues(48.8%, 20/41; 36.6%, 15/41) or gastric adenomas(2/13, 1/13; all P<0.05). HBXIP expression correlated significantly with tumor differentiation and lymph node status (P=0.007; 0.041). Kaplan-Meier survival analysis showed that the overall survival rate was significantly lower in gastric cancer patients with high HBXIP expression (P=0.015). Conclusions: HBXIP expression in gastric cancer is mainly expressed in cytoplasmic, and the expression level is closely related to the prognosis. HBXIP expression status may potentially be used as an important prognostic indicator for gastric cancer. 目的： 探讨乙型肝炎病毒X蛋白结合蛋白(HBXIP)在胃癌细胞株AGS中的定位及其过表达与胃癌患者临床病理参数及预后的关系。 方法： 采用免疫荧光技术检测HBXIP在胃癌细胞株AGS的定位，采用免疫组织化学EnVision法检测HBXIP在97例胃癌组织、41例癌旁非瘤组织和13名正常胃黏膜上皮组织中的表达，并分析HBXIP过表达与胃癌患者病理参数及预后评估之间的关系。 结果： 免疫荧光、免疫组织化学结果显示HBXIP主要定位于胃癌细胞的细胞质，免疫组织化学结果显示HBXIP蛋白在胃癌组织中表达阳性率和强阳性率分别为68.0%(66/97)和49.5%(48/97)，显著高于癌旁非瘤组织(48.8%，20/41；36.6%，15/41)和正常胃黏膜上皮组织(2/13，1/13；P值均<0.05)；卡方检验结果显示，HBXIP表达水平与胃癌患者分化程度、有无淋巴结转移密切相关(P值分别为0.007和0.041)。Kaplan－Meier生存分析表明，HBXIP高表达胃癌患者总生存期显著低于HBXIP低表达的患者(P＝0.015)。 结论： HBXIP表达主要定位于细胞质，表达水平与胃癌的发生发展及预后密切相关。HBXIP表达水平可成为预测胃癌患者预后的重要指标。.
    [Abstract] [Full Text] [Related] [New Search]